Phase 1b segment evaluated safety and tolerability of the combination Paves the way to expand and accelerate enrollment in the Phase 2 segment of the study ROCHESTER, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today reported positive interim safety data in the Phase Ib “safety run-in” segm
NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Home BancShares, Inc. (NASDAQ: HOMB), Valley National Bancorp (NASDAQ: VLY), Kraton Corporation (NYSE: KRA), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Additional information about each potential action can be found at the link provided. Home Bancshares, Inc. (NASDAQ: HOMB) On September 28, 2021, Home BancShares announced that it ha
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Acceleron Pharma Inc. (NASDAQ: XLRN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Merck & Co., Inc. (NYSE: MRK). Click here to learn more and participate in the action. On September 30, 2021, Acceleron announced that it had ent